Coherus is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology treatments that potentially extend patient survival across tumor types. We aim to become a partner of choice for oncology companies seeking to advance combination therapies, including clinical collaborations and/or out-licensing ex-US development/commercial rights, and work with industry partners who can further our mission to deliver medicines that will make an impact for people with life-altering diseases.

If you are interested in collaborating with us, please submit an information request form.